Bupropion increases dopamine and noradrenaline signalling in the brain. It is prescribed for adults with major depressive disorder and, in specific formulations, for smoking cessation; its sustained-release tablets are taken according to an individual prescription.
Bupropion is a prescription antidepressant in the aminoketone class. The product described here contains bupropion hydrochloride in sustained-release tablets. Dosing differs between strengths and between users, so there is no single amount that suits everyone.
Major depressive disorder involves persistent low mood and reduced interest, often alongside changes in sleep, energy, concentration, appetite or motivation. Seasonal affective disorder is a depressive pattern linked to particular seasons. Bupropion is used for these conditions in some regulatory jurisdictions, while licensed indications depend on the formulation and national product information.
The FDA has approved specific bupropion formulations for depressive disorders and seasonal affective disorder. Smoking-cessation use follows a separate product pathway, with its own instructions and treatment schedule. UK prescribing decisions rely on the relevant product information and the clinical assessment of the individual.
Bupropion may be prescribed for depression when its dopamine-and-noradrenaline profile suits the person’s symptoms or previous treatment experience. It may also be selected when sexual dysfunction or weight change has been a concern with another antidepressant, although individual responses differ.
The treatment of smoking cessation uses a structured plan. Bupropion may reduce cravings and withdrawal symptoms, but it does not replace a quit date, behavioural support or follow-up.
Bupropion can support smoking cessation by reducing cravings and withdrawal symptoms. The treatment works best as part of a defined quit plan, with behavioural support and follow-up rather than reliance on tablets alone.
Smoking-cessation protocols differ from depression protocols. The timing of treatment before the quit date, the duration of use and the formulation depend on the licensed product and local prescribing information.
A structured plan generally includes:
Treatment-resistant depression usually means that adequate trials of one or more antidepressants have not produced sufficient improvement. Bupropion may be considered as a switch or as specialist augmentation in selected cases.
This does not mean that adding bupropion is automatically the next step. Clinicians also reassess the diagnosis, adherence, sleep, substance use, medical illness, bipolar features and psychosocial stressors.
Bupropion inhibits the reuptake of dopamine and noradrenaline, also called norepinephrine. Reuptake is the process by which nerve cells remove signalling chemicals from the space between them. By reducing this removal, bupropion can increase signalling linked with alertness, motivation, attention and mood.
Noradrenaline is not the same chemical as adrenaline. Noradrenaline acts extensively as a neurotransmitter in the brain and nervous system, while adrenaline has a stronger role as a circulating stress hormone.
Bupropion does not work through the same primary pathway as selective serotonin reuptake inhibitors. Its clinical effects are more complex than a simple increase in one chemical. Depression involves interacting biological, psychological and social factors, so the same mechanism can produce different results in different people.
Bupropion is described as a dopamine and noradrenaline reuptake inhibitor. This profile may suit depressive symptoms involving low energy, reduced motivation and loss of interest. It can also produce activation, restlessness or sleep difficulty, especially when treatment begins or the dose changes.
The body converts bupropion into active metabolites, including hydroxybupropion. These metabolites contribute to the pharmacological activity of treatment and help explain why the medicine continues to affect the body beyond the time of swallowing an individual tablet.
Bupropion lowers the seizure threshold in a dose-related manner. The risk becomes more concerning with a history of seizures, eating disorders such as bulimia nervosa or anorexia nervosa, abrupt withdrawal from alcohol or sedatives, significant head injury and some interacting medicines.
Important areas include:
Bupropion can inhibit CYP2D6, an enzyme involved in the metabolism of several medicines. This can affect medicines such as some antidepressants, antipsychotics and medicines used for heart rhythm or pain. The listed examples are not a complete interaction database.
NOT for you if you have a seizure disorder, an eating disorder such as bulimia nervosa or anorexia nervosa, or are stopping alcohol or sedatives abruptly without medical supervision.
Bupropion is not suitable for everyone seeking smoking cessation. Seizure history, eating disorders, alcohol withdrawal and interacting medicines require careful screening.
Common adverse effects associated with bupropion include dry mouth, nausea, headache, restlessness and insomnia. Appetite reduction, tremor, sweating, dizziness and anxiety can also occur. The intensity often depends on the formulation, dose and individual sensitivity.
| Possible effect | Practical response |
|---|---|
| Dry mouth or nausea | Sip water, use regular meals and avoid abrupt dose changes |
| Headache or dizziness | Sit down, avoid driving while affected and report persistence |
| Restlessness or insomnia | Take doses at the prescribed daytime times and seek review if severe |
| Seizure or severe behavioural change | Treat as urgent and seek emergency medical help |
Bupropion is often considered when sexual dysfunction or weight gain associated with some serotonin-focused antidepressants is a concern. It can still cause sexual problems in some people, and it may worsen anxiety, agitation or sleep disruption.
Dry mouth can make swallowing, speaking and dental comfort difficult. Regular fluids and good oral hygiene may help. Persistent vomiting, inability to drink or severe nausea needs medical attention. Mild symptoms can fluctuate. Clinical review can guide next steps.
Headache and mild restlessness may settle as the body adapts. New panic, severe irritability or rapidly worsening anxiety is different from mild activation and should be reported.
Antidepressant treatment can be followed by changes in suicidal thinking, agitation, impulsivity or mood elevation. This is especially relevant during treatment initiation and dose changes. Family members or carers may notice behavioural change before the person taking bupropion recognises it.
The product described here contains bupropion hydrochloride in sustained-release tablets, with each tablet containing 150 mg. The pack designation identifies a twice-daily sustained-release formulation.
Bupropion comes in immediate-release, sustained-release and extended-release formulations in different markets. These formulations cannot be treated as interchangeable because the release rate changes how often the tablets are taken and how much active substance enters the bloodstream at one time.
The product sold here is a sustained-release tablet formulation. A sustained-release tablet releases bupropion gradually rather than delivering the full amount immediately.
The exact dose differs between strengths, formulations and individuals, so there is no single amount that suits everyone. Dose timing can matter. The sustained-release tablets described here are marked for twice-daily use, but the prescriber determines the appropriate starting plan, dose changes and treatment duration.
The UK Summary of Product Characteristics provides formulation-specific dosing and administration information. A prescriber may begin cautiously and review response, sleep, anxiety, blood pressure, mood changes and tolerability before making an adjustment.
Crushing, chewing or splitting a sustained-release tablet can alter the release pattern. This may expose the body to too much bupropion at once and increase adverse effects, including seizure risk.
One easy mistake is to treat a scored-looking tablet as automatically safe to divide. The appearance of a tablet does not determine whether it can be split.
Some people notice changes in energy, concentration or sleep before mood improves. Antidepressant benefit often requires several weeks of regular treatment, with review based on symptom change and adverse effects rather than on one difficult day.
Urgent help is needed for suicidal thoughts, severe confusion, a seizure, hallucinations, extreme agitation or symptoms suggesting mania, such as very little sleep with unusually high energy and impulsive behaviour.
Bupropion, SSRIs and SNRIs influence different neurotransmitter systems. The choice depends on symptoms, previous response, adverse effects, physical health and interaction risks.
| Class or medicine | Main pharmacological profile and trade-off |
|---|---|
| Bupropion | Dopamine and noradrenaline reuptake inhibition; may cause activation, dry mouth or insomnia |
| SSRIs, such as sertraline or fluoxetine | Serotonin reuptake inhibition; useful for many depressive and anxiety disorders, with possible nausea or sexual dysfunction |
| SNRIs, such as venlafaxine | Serotonin and noradrenaline reuptake inhibition; may help depression and some pain syndromes, with possible nausea, sweating or blood-pressure effects |
Bupropion may have a lower rate of sexual dysfunction than some SSRIs, but the risk is not zero. SSRIs can be preferable when anxiety, panic symptoms or obsessive symptoms dominate. SNRIs may be considered when depression occurs alongside certain chronic pain conditions, though blood pressure and withdrawal symptoms require attention.
Alternative antidepressants are selected by treatment profile rather than by a universal ranking. Escitalopram and citalopram are SSRIs. Duloxetine is an SNRI. Mirtazapine has sedating and appetite-increasing properties for some people, while amitriptyline is a tricyclic antidepressant with a broader adverse-effect burden.
Buspirone is used for anxiety and is not a rapid tranquilliser. It does not provide immediate relief in the same way as a sedative medicine.
Switching, combining or tapering these medicines requires an individual plan. Abrupt antidepressant changes can produce withdrawal symptoms or destabilise mood.
One detail patients often miss is that symptom improvement and adverse effects do not follow the same timetable. Another is that a missed dose should not be “made up” by taking extra medicine later.
In clinical practice, prescribers often view bupropion as a useful option when low energy, reduced motivation or antidepressant-related sexual dysfunction affects treatment decisions. The same activating profile can be uncomfortable for a person with severe anxiety, insomnia or agitation.
A doctor will usually want a clear history of seizures, eating disorders, alcohol use, sedative use, bipolar symptoms and all current medicines before prescribing. This screening is not paperwork; it changes whether bupropion is suitable and how it should be monitored.
Bupropion can be helpful without being a universal first choice. Response should be judged by functioning, mood, sleep, concentration and safety, not only by whether the person feels more alert.
Bupropion is not routinely used for depression in children and adolescents, and use under 18 requires a specialist decision based on the formulation and clinical circumstances. The MHRA’s safety approach to antidepressants includes close monitoring of suicidal thinking and behavioural change in younger people. In 2025 UK clinical practice, treatment choices for under-18s generally follow child and adolescent mental-health guidance rather than adult prescribing patterns.
Yes, insomnia is a recognised adverse effect of bupropion because its activating pharmacological profile can affect sleep. The UK Summary of Product Characteristics and MHRA safety information support taking prescribed doses at appropriate times and reviewing persistent sleep disruption. In 2025 clinical practice, severe insomnia, agitation or rapidly worsening anxiety warrants prompt assessment rather than repeated self-adjustment.
Bupropion mainly affects dopamine and noradrenaline reuptake, while an SSRI such as sertraline mainly increases serotonin signalling. NICE guidance available in 2025 describes antidepressant selection as dependent on symptoms, previous response, adverse effects and patient preference. Bupropion may cause less sexual dysfunction for some people, while SSRIs may suit prominent anxiety more readily.
A sustained-release tablet is designed to release bupropion over an extended period, which is why the product is marked for twice-daily administration. The FDA prescribing information explains that modified-release formulations must be used according to their specific schedule rather than substituted dose-for-dose. In 2025 pharmacology practice, the duration of effect is understood as formulation-dependent, not as a fixed number of hours for every person.
Regular sleep, consistent dosing times, reduced alcohol exposure and behavioural support can make treatment easier to assess. Irregular sleep, heavy alcohol use, abrupt sedative withdrawal and stimulant use can worsen adverse effects or seizure risk. WHO depression guidance published in 2023 supports combining medicine with practical psychological and lifestyle support where appropriate.
Bupropion sustained-release tablets may be taken with or without food when used according to the prescribed instructions. Taking a dose with food may feel easier for someone who experiences nausea, but food does not remove the need to follow the correct interval between doses. The Electronic Medicines Compendium product information current before 2026 describes formulation-specific administration, so the prescribed instructions take priority over personal experimentation.
Treatment duration depends on the condition, response, relapse history and tolerability. NICE guidance reviewed in 2022 supports continuing antidepressant treatment after recovery for people at meaningful risk of relapse, with periodic review of benefit and adverse effects. Long-term bupropion can be appropriate for some adults, while others need a planned taper or a different strategy; stopping suddenly is not a substitute for clinical review.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first week brought a dry mouth and a restless feeling in the evenings. Sleep improved after I took the second dose earlier, and by the fourth week I was getting more done in the morning. I still had some anxious days, so the improvement was gradual rather than dramatic.
My energy was better after several weeks, and I did not notice the sexual side effects I had experienced with an earlier antidepressant. Headaches were irritating at the start. I also needed a review because my blood pressure readings were higher than usual.
Cravings became easier to manage when I combined the tablets with a quit plan. The first nights were poor because of insomnia, and I nearly stopped. Changing the timing through the prescribed plan helped, but the medicine alone would not have been enough.
